Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

ENTA’s phase-2b trial in RSV misses primary endpoint:

Disappointing news but this doesn't mean the end of the RSV program but it is delayed and in trouble. The fact the challenge trial was successful gives me some hope that the high risk population might fare better than the healthy population in the failed phase 2b. Add in that the L protein inhibitor will soon enter trials a combination trial could be in the future.

On the heels of this disappointing RSV trial, ENTA is riskier now given the HepB program is on hold until ENTA gets their second drug into trials. Unless one is found or ENTA can find another company to provide that second drug, everything in the rest of the year rides on EDP-235.